Tirzepatide: The Pioneer of Dual GIP and GLP-1 Receptor Agonism

Tirzepatide is a pioneer in incretin biology, serving as the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.⁴

Structural Parameters of Tirzepatide

Origin, History, and Research Stage

Tirzepatide was synthesized by Eli Lilly and Company, with initial patent applications filed in early 2016 . Following the SURPASS and SURMOUNT clinical trial programs, Tirzepatide demonstrated superior glycemic control and weight reduction compared to selective GLP-1 agonists.⁸ Tirzepatide received US FDA approval as Mounjaro for type 2 diabetes on May 13, 2022, and as Zepbound for chronic weight management in November 2023 . Its core compound patent provides Eli Lilly with an exclusivity runway stretching to 2036–2038 in major Western markets.⁴ Clinical trials completed in 2024 (e.g., the SUMMIT trial) have expanded its investigational scope to obesity-related heart failure with preserved ejection fraction (HFpEF), chronic kidney disease, and MASH.⁸

Mechanism of Action and Pharmacokinetics

Tirzepatide acts as a balanced dual agonist.⁸ It is a full agonist at the GIP receptor, displaying an in vitro potency similar to native GIP (EC50 = 0.042 nM), while acting as a biased agonist at the GLP-1 receptor (EC50 = 0.086 nM).8 This bias favors cyclic AMP (cAMP) signaling over beta-arrestine recruitment, which reduces receptor internalization and sustains receptor activation.⁸ The peptide's structural backbone is acylated at Lys20 with a C20 fatty diacid (eicosanedioic acid) via a gamma-glutamyl spacer.⁸ This modification enables high-affinity binding to serum albumin, resulting in an elimination half-life of approximately 5 days and permitting once-weekly subcutaneous dosing.⁸ GIP receptor activation in adipose tissue improves insulin sensitivity and buffering capacity, while synergistic GIPR and GLP-1R signaling in the brainstem and hypothalamus coordinates appetite suppression.8